NASDAQ:AKTX Akari Therapeutics (AKTX) Stock Price, News & Analysis → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free AKTX Stock Alerts $1.55 +0.03 (+1.97%) (As of 05/20/2024 ET) Add Compare Share Share Today's Range$1.50▼$1.6050-Day Range$1.16▼$2.1552-Week Range$1.08▼$5.50Volume22,630 shsAverage Volume23,827 shsMarket Capitalization$12.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Akari Therapeutics alerts: Email Address Ad True Market InsidersExposed: 10 CENT Crypto to Explode May 20th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About Akari Therapeutics Stock (NASDAQ:AKTX)Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Read More AKTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKTX Stock News HeadlinesMay 18 at 5:52 AM | americanbankingnews.comAkari Therapeutics (NASDAQ:AKTX) Shares Pass Below 200-Day Moving Average of $2.40May 18 at 3:52 AM | americanbankingnews.comAkari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.comMay 16, 2024 | finance.yahoo.comAkari Therapeutics Reports First Quarter 2024 Financial Results and Recent HighlightsMay 16, 2024 | globenewswire.comAkari Therapeutics Reports First Quarter 2024 Financial Results and Recent HighlightsMay 11, 2024 | americanbankingnews.comAkari Therapeutics, Plc (NASDAQ:AKTX) Sees Large Growth in Short InterestMay 2, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday TradingMay 1, 2024 | msn.comAkari gains despite leadership change amid portfolio shakeupMay 1, 2024 | markets.businessinsider.comAkari Therapeutics Appoints Samir Patel Interim CEO After CEO Rachelle Jacques Steps DownMay 1, 2024 | globenewswire.comSamir R. Patel, M.D. Appointed Interim CEO for Akari TherapeuticsMay 1, 2024 | globenewswire.comAkari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger EntityApril 15, 2024 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024April 15, 2024 | globenewswire.comAkari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024April 12, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Lower in Friday TradingApril 12, 2024 | msn.comDindin lethal in Akari’s disposal of Capital1April 1, 2024 | finance.yahoo.comAkari Therapeutics Insider Ups Holding By 69% During YearApril 1, 2024 | globenewswire.comAkari Therapeutics Reports Full-Year 2023 Financial Results and Recent HighlightsMarch 17, 2024 | msn.comPVL: Fifi Sharma, Ced Domingo power Akari romp of NxledMarch 7, 2024 | bizjournals.comPetri Dish: C4’s deal with Merck KGaA; Boston and California biotechs mergeMarch 6, 2024 | stockhouse.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AKTX, HES, TGAN, NSMarch 5, 2024 | businesswire.comAKTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Akari Therapeutics, Plc Is Fair to ShareholdersFebruary 27, 2024 | msn.comPVL: Grethcel Soltones, Akari still a work in progressFebruary 25, 2024 | msn.comPVL: Ced Domingo has a quiet Akari debut as she adjusts to new systemFebruary 24, 2024 | msn.comPVL: Cignal turns back Akari to open All-Filipino bidFebruary 16, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Set to End Week Higher in Friday TradingFebruary 9, 2024 | msn.comPVL: Akari’s Max Juangco taking pressure of her pro debut in strideSee More Headlines Receive AKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/31/2020Today5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AKTX CUSIPN/A CIK1541157 Webwww.akaritx.com Phone442080040261Fax646-843-9352Employees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.44 Quick Ratio0.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-51.67Miscellaneous Outstanding Shares7,920,000Free Float3,027,000Market Cap$12.28 million OptionableNot Optionable Beta0.99 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMs. Rachelle Suzanne Jacques (Age 53)President, CEO & Director Comp: $632.25kMs. Wendy F. DiCicco CPA (Age 57)Interim Chief Financial Officer Comp: $540.34kMs. Melissa Bradford-Klug (Age 54)Chief Operating Officer Dr. Miles Nunn (Age 55)Chief Scientific Officer Dr. John F. Neylan III (Age 71)M.D., Executive VP & Chief Medical Officer Key CompetitorsMonopar TherapeuticsNASDAQ:MNPRABVC BioPharmaNASDAQ:ABVCElevai LabsNASDAQ:ELABAvalo TherapeuticsNASDAQ:AVTXMIRA PharmaceuticalsNASDAQ:MIRAView All Competitors AKTX Stock Analysis - Frequently Asked Questions How have AKTX shares performed in 2024? Akari Therapeutics' stock was trading at $3.12 at the start of the year. Since then, AKTX shares have decreased by 50.3% and is now trading at $1.55. View the best growth stocks for 2024 here. How were Akari Therapeutics' earnings last quarter? Akari Therapeutics, Plc (NASDAQ:AKTX) released its quarterly earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.80) by $5.00. When did Akari Therapeutics' stock split? Akari Therapeutics shares reverse split before market open on Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Akari Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Biocept (BIOC), OPKO Health (OPK), Anavex Life Sciences (AVXL), Rigel Pharmaceuticals (RIGL), Teva Pharmaceutical Industries (TEVA), Vascular Biogenics (VBLT) and Heat Biologics (HTBX). How do I buy shares of Akari Therapeutics? Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AKTX) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDoes this make you sick?Allegiance Gold[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersBill Gates is all about this tiny $2 stockTimothy SykesThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldBill Clinton Backing Biden Replacement???The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics, Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.